IBC Meeting Minutes
9/10/2026 12:05 PM
CMRI Conference Room 31 & Teams

MEETING TIME RECORDS

Meeting start time: 12:07
Meeting end time: 13:04

VOTING MEMBER ATTENDANCE

Name of IBC Member	Committee Role	Late Arrival Time	Early Departure Time
Daniel Heruth	Chair, Animal Expert, Lab Rep		
Todd Bradley	Co-Chair, Lab Rep		
Paul Ramlow	BSO, Animal Expert, Lab Rep		
Judy Dilts	Local Non-Affiliated		
Tamie Crutchfield	Occupational Health		

VOTING MEMBERS ABSENT

Tarak Srivastava	Lab Rep		
James Slaughter	Local Non-Affiliated		

ALTERNATES PRESENT BUT NON-VOTING

Vivekanand Yadav	Alternate Lab Rep		

NON-VOTING MEMBERS PRESENT

Foster St. Claire	AV & Ex-Officio		

ADMINISTRATIVE STAFF

Saskia Miller	Director of the ORI		
Lizzie Short	Associate Director of the IBC		
Daniel Crabtree	Sr. IBC Manager		
Kelleigh Pearson	Administrative Project Coordinator		

QUORUM INFORMATION

Number of SAFETY members on the roster: 7

GUEST NAMES

[redacted]

Conflict of Interest (COI): Chair reminded the Committee to declare any COI.

Previous Meeting minutes approved: Yes
A motion to approve was made and seconded. The motion passed with 4 yes, 1 abstained, 2 absent.

BIOSAFETY COMMITTEE UPDATES

1. **Biological Safety Officer (BSO) Updates**
   The BSO reported on recent laboratory inspections and training activities conducted during the reporting period. No incidents, safety concerns, or compliance issues were identified, and laboratory operations were found to be in good standing.

   The BSO and Associate Director, IBC provided an overview of the NIH Draft Biosafety Policy for Research Involving Biohazards, which has been released for public comment. Key elements of the draft policy and its potential implications for institutional biosafety oversight were discussed.
2. **Office of Research Integrity (ORI) Updates**
   The Vice Chair had the IBC members introduce themselves to the EQuIP Fellowship members and welcomed them to the Committee.

   The Associate Director, IBC reminded the Committee of the ongoing vote on the Minors in Research Policy. The Committee discussed comments received during the review period, including considerations related to assessing the competency of minor participants to work with risk group 2 materials and the process for making such determinations. The BSO discussed the assessment process.

REVIEW OF SUBMISSIONS

De Novo Review

3. **Review of IBC00125**

Title:	E. coli Infections in Newborns and Infants
Investigator:	Susana Chavez-Bueno
Submission ID	IBC00125
Attempt to Express Foreign Genes:	E. coli mutants will constitutively express the inserted chloramphenicol, tetracycline and GFP genes which will confer antibiotic resistance to the antibiotics and a green fluorescence phenotype. The strains will be grown in antibiotic-containing media for appropriate phenotypic selection.
Protein Produced:	None
Agent Characteristics:	**Biological Agent Sources:** ATCC, UMKC LARC, Sigma (Catalog No. 88011801-1VL), Clinical Laboratory at Children's Mercy Hospital in Kansas

	City, MO, Creative Biolabs, Invitrogen, Clinical isolates from clinical microbiology laboratories. **Recombinant Nucleic Acid Work:** Site-specific gene deletion mutants will be created in E. coli with the lambda-red recombinase method of gene replacement using plasmids pKD46 or pKD47, and pKD3. Complementation of each deletion mutant confirmed to have a phenotype of decreased invasion or transcytosis of intestinal cells, will be performed by cloning the corresponding gene of interest in pACYC184. We will also construct and screen a transposon library using E. coli isolates and the EZ-Tn5 transposon kit by Lucigen® (https://www.lucigen.com/EZ-Tn5-KAN-2-TET-1-DHFR-1-Insertion-Kits/). Transgene insertion will be created using pMRE-Tn7-132 or pMRE-Tn7-133 plasmid purchased from addgene (http://www.addgene.org/118550/) Vectors: pKD46, pKD47, pKD3 and pACYC184. These plasmids will be used to make chromosomal gene deletions or complementations. pkD46 carries the λ red genes behind the araBAD promoter. It has the gene for ampicillin resistance. pKD47 is a derivative of pDK46 where the blaM gene is replaced with spectinomycin resistance gene. pkD3 has the chloramphenicol resistance cassette. The resistance cassettes are flanked by flippase recognition target (FRT) sites, which allow the removal of the cassettes once inserted in the bacterial chromosome with a flippase(FLP) helper plasmid. pACYC184 has the p15A origin of replication and the gene for tetracycline and chloramphenicol resistance. This allows it to coexist in cells with the ColE1 compatibility group. The transposon we will use to build a library of mutants in E. coli contains a tetracycline resistance gene flanked by 19 bpTn5 transposase recognition sequences. pMRE-Tn7-132: miniTn7 plasmid to deliver constitutively expressed green fluorescent protein and chloramphenicol resistance genes in bacteria. pMRE-Tn7-133: miniTn7 plasmid to deliver constitutively expressed yellow fluorescent protein and chloramphenicol resistance genes in bacteria.

Agent Containment:	**Biological Containment Levels:** • Lactobacillus crispatus: BSL-1 • Ect1/E6E7: BSL-2 • VK2/E6E7: BSL-2 • BJ: BSL-2 • Lactobacillus iners: BSL-1 • Lactobacillus gasseri: BSL-1 • Rat Tissue: BSL-2 • Mouse Tissue: BSL-2 • HIEC-6 (ATCC® CRL-3266): BSL-2 • T84 (ATCC® CCL-248™): BSL-2 • Other: BSL-1 • Streptococcus pneumoniae: BSL-2 • Escherichia coli Nissle 1917: BSL-1 • Escherichia coli (DH5 alpha, One Shot Top10, and Mach1): BSL-1 • Escherichia coli (strains bearing K1 antigen) : BSL-2 • lactobacillus rhamnosus : BSL-1 • Bifidobacterium spp.: BSL-1 • Streptococcus agalactiae : BSL-2
Applicable NIH Guidelines:	• Section III-D-1-a • Section III-D-1 • Section III-D

Determination: Modifications Required

Required modifications:

1. Update human cell cultures to BSL2.
2. Be specific about the source of materials (e.g. Clinical isolates from clinical Microbiology laboratories vs CMH clinical Microbiology laboratories).
3. In addition to culture volume, include the estimated number of cultures that will be collected.
4. Describe which genes are being manipulated and their function in E. coli.
5. Manipulation of virulence factors is mentioned but not described. Please describe this work. The protocol should reflect only the activities currently being conducted. If this work is not currently taking place, please omit and add by amendment once planned.
6. The protocol involves manipulating clinical strains to increase antibiotic resistance and change pathogenicity such as invasion. In the Dual Use Research of Concern section, clearly explain that there is no enhancement of pathogenicity or drug resistance. Also indicate if any pathogens of concern are being worked with.
7. Update the consequences of exposure to indicate that the employees should follow the standard exposure protocol and immediately report the exposure incident to Occupational Health. The incident should also be documented in

the Team Member Safety icon in the RL reporting system. If an employee develops signs or symptoms of illness related to the exposure, Occupational Health will refer the employee to the Occupational Medicine provider for evaluation and treatment, as appropriate.

8. Please move the spill cleanup information into the Exposure and Assessment section of the protocol.

Comments:

The BSO provided an overview of the triennial review.

The Committee discussed the funding source associated with the protocol. Following discussion, it was determined that the funding was provided by the department, and the reviewer agreed to withdraw the comment.

The Committee noted that human cell culture work should be conducted at Biosafety Level 2 (BSL-2), despite ATCC listing it as BSL1 for shipping purposes, and requested that the protocol be updated accordingly.

The protocol does not consistently specify the source of biological materials. The Committee requested more specific descriptions of specimen sources.

While culture volumes are provided, the protocol does not indicate the anticipated number of cultures to be collected. The Committee requested inclusion of the estimated number of cultures in addition to culture volume to better assess project scope and biosafety requirements.

The Committee requested additional details regarding the genes being manipulated in E. coli, including identification of the specific genes and an explanation of their biological function. The protocol references manipulation of virulence factors but does not adequately describe the planned activities. The Committee requested a detailed description of this work. The Chair noted that the protocol should reflect only the activities currently being conducted and recommended revising the narrative to focus on the current scope of work.

The Committee reviewed comments regarding the exposure control section and requested additional revisions to indicate that standard exposure response procedures will be followed.

Additional information was requested regarding the Dual Use Research of Concern (DURC) assessment, including justification for why the proposed work does not meet DURC criteria.

The Committee recommended revisions to the Waste Management section to improve the organization and placement of relevant information.

A motion was made to require modifications prior to approval. The motion carried with 5 votes in favor, 0 against, and 2 members absent.

Supporting documents:
None

Votes:

For:	5
Against:	0
Recused:	0
Absent:	2
Abstained:	0

De Novo Review

4. [redacted]

[redacted]

[redacted]

[redacted]

REVIEW OF OTHER AGENDA ITEMS

[redacted]

ACKNOWLEDGMENTS SECTION

The following items were approved outside of a convened IBC meeting. The Committee reviewed and acknowledged the following items during this meeting.

ID	Name	State	Specialist	Agenda Type
CR202600007	Continuing Review for IBC00092	Approved	Elizabeth Short	Admin Approval
IBC00127	Endotyping Sepsis-AKI	Approved	Elizabeth Short	Admin Approval
SAMEND202600004	Amendment for IBC00104	Approved	Daniel Crabtree	Admin Approval
SAMEND202600033	Amendment for IBC00089	Approved	Daniel Crabtree	Admin Approval
SAMEND202600040	Amendment for IBC00111	Approved	Daniel Crabtree	Admin Approval
SAMEND202600041	Amendment for IBC00119	Approved	Daniel Crabtree	Admin Approval
SAMEND202600042	Amendment for IBC00116	Approved	Daniel Crabtree	Admin Approval

ID	Name	State	Specialist	Agenda Type
SAMEND202600043	8-26 Amendment for IBC00099	Approved	Elizabeth Short	Admin Approval
SAMEND202600044	Amendment for IBC00123	Approved	Daniel Crabtree	Admin Approval
SAMENDCR202600005	Amendment/CR for IBC00098	Approved	Daniel Crabtree	Admin Approval